CVO-035

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCVO-035
Drug Alias Nameanticancer monoclonal antibody (Caveo)mer receptor tyrosine kinase inhibitors (Caveo Therapeutics)CVO-035
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTyrosine-protein kinase Mer inhibitors
TargetsTyrosine-protein kinase Mer
Therapy Area/IndicationsThrombosisCarcinoma, Non-Small-Cell LungGlioblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCaveo Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesColorado Institute For Drug, Device & Diagnostic DevelopmentCaveo Therapeutics
Active IndicationsN/A
Inactive IndicationsThrombosisCarcinoma, Non-Small-Cell LungGlioblastoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A